Abstract: This invention is directed to 4-amino-17.beta.-(cyclopropyloxy)androst-4-en-3-one, 4-amino-17.beta.-(cyclopropylylamino)androst-4-en-3-one and related compounds, a process for their synthesis, a pharmaceutical composition having C.sub.17-20 lyase and 5.alpha.-reductase inhibitory activity, the use of the present compounds as C.sub.17-20 lyase and 5.alpha.-reductase inhibitors and also to a method for using such compounds in the treatment of androgen and/or estrogen dependent disorders, including bengin prostatic hyperplasia, breast cancer and prostatic cancer. The 4-amino compounds are prepared by the reaction of the appropriate 4,5-epoxide with sodium azide in an inert solvent in the presence of a catalytic amount of strong acid under appropriate reaction conditions. Alternatively, the 4-amino compounds are prepared by first nitration and then reduction of the appropriate steroid under appropriate reaction conditions.
Type:
Grant
Filed:
May 2, 1994
Date of Patent:
January 23, 1996
Assignee:
Merrell Dow Pharmaceuticals Inc.
Inventors:
Philip M. Weintraub, Cynthia A. Gates, Michael R. Angelastro, Timothy T. Curran, J. O'Neal Johnston
Abstract: The present invention relates to novel 2-substituted indane-2-mercaptoacetylamide derivatives which are useful as inhibitors of enkephalinase and ACE.
Abstract: This invention relates to alkylated sulfonium alkylene derivatives of certain 2H-1-benzopyrans, to the intermediates and processes useful for their preparation, to their free-radical scavenger and cardioprotective properties and to their end-use application as therapeutic agents.
Type:
Grant
Filed:
February 28, 1995
Date of Patent:
January 16, 1996
Assignee:
Merrell Dow Pharmaceuticals Inc.
Inventors:
J. Martin Grisar, Margaret A. Petty, Frank Bolkenius
Abstract: The present invention is directed to a class of 4,6-disubstituted tryptophan derivatives, 4,6-disubstituted kynurenines, their use as NMDA antagonists and to pharmaceutical compositions containing these compounds.
Type:
Grant
Filed:
December 10, 1993
Date of Patent:
January 16, 1996
Assignee:
Merrell Dow Pharmaceuticals Inc.
Inventors:
Michael G. Palfreyman, Ian Alexander McDonald, Francesco G. Salituro, Robert Schwarcz
Abstract: The present invention relates to the use of certain mercaptoacetylamide and benzazapine derivatives in treating patients suffering from hypertriglyceridemia, atherosclerosis and hypercholesterolemia.
Type:
Grant
Filed:
March 24, 1994
Date of Patent:
January 16, 1996
Assignee:
Merrell Dow Pharmaceuticals Inc.
Inventors:
Gary A. Flynn, John F. French, Richard C. Dage
Abstract: This invention relates to novel morpholinourea and related derivatives of pentafluoroethyl peptides which are orally active elastase inhibitors. These compounds are useful in the treatment of various inflammatory diseases and emphysema.
Type:
Grant
Filed:
October 13, 1994
Date of Patent:
December 26, 1995
Assignee:
Merrell Dow Pharmaceuticals Inc.
Inventors:
Norton P. Peet, Michael R. Angelastro, Joseph P. Burkhart
Abstract: The present invention is direct to a new class of 1-piperidinyl alkanoarylsulfonamides of the formula I ##STR1## wherein R, X, m, n, and Alk are defined in the specification, and their use as antiarrhythmic agents.
Type:
Grant
Filed:
July 22, 1994
Date of Patent:
December 26, 1995
Assignee:
Merrell Dow Pharmaceuticals Inc.
Inventors:
Albert A. Carr, Richard C. Dage, Thaddeus R. Nieduzak, John E. Koerner, Tung Li
Abstract: The invention relates to compounds of the formula ##STR1## wherein B.sub.1 and B.sub.2 are each independently hydrogen; hydroxy; --OR.sub.2 wherein R.sub.2 is a C.sub.1 -C.sub.4 alkyl or an Ar--Y group wherein Ar is aryl and Y is a hydrogen or C.sub.1 -C.sub.4 alkyl; or, where B.sub.1 and B.sub.2 are attached to adjacent carbon atoms, B.sub.1 and B.sub.2 can be taken together with said adjacent carbons to form a benzene ring or methylenedioxy;A is a bond, methylene or oxygen, sulfur, NR.sub.4 or NCOR.sub.5 wherein R.sub.4 is hydrogen, a C.sub.1 -C.sub.4 alkyl or an Ar--Y-- group and R.sub.5 is --CF.sub.3, a C.sub.1 -C.sub.10 alkyl or an Ar--Y-- group; R.sub.3 is hydrogen or --CH.sub.2 OC(O)C(CH.sub.3).sub.3 ; R.sub.1 is hydrogen, C.sub.1 -C.sub.4 alkyl or --CH.sub.2 OC(O)--C(CH.sub.3).sub.3 ; and n is an integer 1 to 3,that are useful as inhibitors of enkephalinase and ACE.
Abstract: This invention relates to a novel synthesis of 4-amino-5-hexenoic acid by thermal rearrangements, and to the novel intermediates produced thereby.
Abstract: The present invention is directed to a class of 3-phosphono-pyrrolidine derivatives as described by Formula I and their use as NMDA antagonists.
Abstract: The present invention is directed to a class of 4,6-disubstituted tryptophan derivatives, 4,6-disubstituted kynurenines, their use as NMDA antagonists and to pharmaceutical compositions containing these compounds.
Type:
Grant
Filed:
June 17, 1994
Date of Patent:
November 28, 1995
Assignee:
Merrell Dow Pharmaceuticals Inc.
Inventors:
Michael G. Palfreyman, Ian A. McDonald, Francesco G. Salituro, Robert Schwarcz, Bruce M. Baron
Abstract: The present invention relates to a method of effecting immunosuppression in a patient in need thereof comprising administering to said patient an effective immunosuppressive amount of certain 5'-vinylhalo-aristeromycin/adenosine analogs.
Type:
Grant
Filed:
June 16, 1994
Date of Patent:
November 28, 1995
Assignee:
Merrell Dow Pharmaceuticals Inc.
Inventors:
Jeffrey A. Wolos, Niall S. Doherty, Esa T. Jarvi, James R. McCarthy
Abstract: The present invention relates to compounds of the formula ##STR1## wherein A is methylene, oxygen, sulfur or N--B wherein B is R.sub.1 or COR.sub.2 wherein R.sub.1 is hydrogen, a C.sub.1 -C.sub.4 alkyl or an Ar--Z--group wherein Ar is aryl and Z is a C.sub.0 -C.sub.4 alkyl and R.sub.2 is a --CF.sub.3, a C.sub.1 -C.sub.10 alkyl or an Ar--Z group;R is hydrogen or a C.sub.1 -C.sub.4 alkyl; andX and Y are each independently hydrogen, nitro or amino, with the proviso that when X is nitro or amino, Y must be hydrogen, and when Y is nitro or amino, X must be hydrogen; andpharmaceutically acceptable salts thereof, which are inhibitors of Angiotensin Converting Enzyme.
Abstract: The oligomers of the present invention are polyureas or polyamides having a number average molecular weight of <10,000. These oligomers are water-soluble, have a rigid backbone with a predictable anion spacing, and are pharmaceutically-acceptable. The oligomers are useful for inhibiting the proliferation of smooth muscle cell.
Type:
Grant
Filed:
June 15, 1993
Date of Patent:
October 24, 1995
Assignee:
Merrell Dow Pharmaceuticals Inc.
Inventors:
Alan D. Cardin, Steven J. Busch, Masayuki Mano
Abstract: The present invention relates to compounds of the formula ##STR1## wherein B.sub.1 and B.sub.2 are each independently hydrogen; hydroxy; --OR.sub.2 wherein R.sub.2 is a C.sub.1 -C.sub.4 alkyl or an Ar--Y group wherein Ar is aryl and Y is a hydrogen or C.sub.1 -C.sub.4 alkyl; or, where B.sub.1 and B.sub.2 are attached to adjacent carbon atoms, B.sub.1 and B.sub.2 can be taken together with said adjacent carbons to form a benzene ring or methylenedioxy;A is a bond, methylene or oxygen, sulfur or NR.sub.4 or NCOR.sub.5 wherein R.sub.4 is hydrogen, a C.sub.1 -C.sub.4 alkyl or an Ar--Y-- group and R.sub.5 is --CF.sub.3, a C.sub.1 -C.sub.10 alkyl or an Ar--Y-- group;R.sub.3 is hydrogen or --CH.sub.2 OC(O)C(CH.sub.3).sub.3 ;R.sub.1 is hydrogen, C.sub.1 -C.sub.4 alkyl or --CH.sub.2 OC(O)--C(CH.sub.3).sub.3 ; andn is an integer 1 to 3,which are useful as inhibitors of enkephalinase and ACE.
Abstract: A method for the inhibition of tumor metastases is described herein. The method makes use of the administration of an antimetastatic factor isolated from the leech Haementeria ghilianii.
Abstract: This invention relates to 1-phenyl-3-phenyl-2-propyne-1-ones, the use of these compounds as calcium uptake inhibitors in leukocytes and thrombocytes, and pharmaceutical compositions containing these compounds as active ingredients, and the process of their preparation.
Type:
Grant
Filed:
September 16, 1994
Date of Patent:
August 29, 1995
Assignee:
Merrell Dow Pharmaceuticals Inc.
Inventors:
Robert J. Dinerstein, Jeffrey S. Sabol, Keith A. Diekema